{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:22Z","timestamp":1791665962359,"version":"4.3.4"},"reference-count":45,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1210\/jc.2017-01624","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T18:05:38Z","timestamp":1505844338000},"page":"4323-4332","source":"Crossref","is-referenced-by-count":90,"title":["Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors"],"prefix":"10.1210","volume":"102","author":[{"given":"Judith E K","family":"Henning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Deutschbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Steinhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviu","family":"Sbiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Schl\u00f6telburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina L","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"issue":"2","key":"key\n\t\t\t\t20171106135751_B1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","year":"2014","journal-title":"Endocr Rev"},{"issue":"12","key":"key\n\t\t\t\t20171106135751_B2","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t20171106135751_B3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"German Adrenocortical Carcinoma Registry Group","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171106135751_B4","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"ENSAT Network","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"key\n\t\t\t\t20171106135751_B5","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0273","article-title":"EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?","volume":"171","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t20171106135751_B6","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","year":"2012","journal-title":"Ann Oncol"},{"issue":"23","key":"key\n\t\t\t\t20171106135751_B7","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"FIRM-ACT Study Group","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"key\n\t\t\t\t20171106135751_B8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"key\n\t\t\t\t20171106135751_B9","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20171106135751_B10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/00498250801927427","article-title":"Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins","volume":"38","year":"2008","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20171106135751_B11","first-page":"13","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","year":"2015","journal-title":"Front Pharmacol"},{"issue":"19","key":"key\n\t\t\t\t20171106135751_B12","first-page":"4349","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","year":"1998","journal-title":"Cancer Res"},{"issue":"20","key":"key\n\t\t\t\t20171106135751_B13","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"key\n\t\t\t\t20171106135751_B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"key\n\t\t\t\t20171106135751_B15","first-page":"djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"European Study Group for Pancreatic Cancer","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"key\n\t\t\t\t20171106135751_B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/156800911793743600","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)","volume":"11","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"key\n\t\t\t\t20171106135751_B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7819-11-117","article-title":"Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone","volume":"11","year":"2013","journal-title":"World J Surg Oncol"},{"issue":"2 Pt 2","key":"key\n\t\t\t\t20171106135751_B18","first-page":"E110","article-title":"The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy","volume":"108","year":"2011","journal-title":"BJU Int"},{"issue":"7","key":"key\n\t\t\t\t20171106135751_B19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","year":"2011","journal-title":"Lancet Oncol"},{"issue":"32","key":"key\n\t\t\t\t20171106135751_B20","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/onc.2009.158","article-title":"Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma","volume":"28","year":"2009","journal-title":"Oncogene"},{"issue":"12","key":"key\n\t\t\t\t20171106135751_B21","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"key\n\t\t\t\t20171106135751_B22","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12672-016-0260-7","article-title":"Salvage treatment of adrenocortical carcinoma with trofosfamide","volume":"7","author":"German Adrenocortical Carcinoma Study Group","year":"2016","journal-title":"Horm Cancer"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1677\/ERC-08-0224","article-title":"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy","volume":"16","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"14","key":"key\n\t\t\t\t20171106135751_B26","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1002\/cncr.25883","article-title":"Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer","volume":"117","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"key\n\t\t\t\t20171106135751_B27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cncr.27739","article-title":"Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy","volume":"119","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdm576","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer","volume":"19","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/jcp.22869","article-title":"New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells","volume":"227","year":"2012","journal-title":"J Cell Physiol"},{"issue":"10","key":"key\n\t\t\t\t20171106135751_B30","doi-asserted-by":"crossref","first-page":"e107973","DOI":"10.1371\/journal.pone.0107973","article-title":"Human equilibrative nucleoside transporter-1 knockdown tunes cellular mechanics through epithelial-mesenchymal transition in pancreatic cancer cells","volume":"9","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1677\/ERC-08-0211","article-title":"Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma","volume":"16","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"key\n\t\t\t\t20171106135751_B32","doi-asserted-by":"crossref","first-page":"E2251","DOI":"10.1210\/jc.2012-2669","article-title":"Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/ERC-15-0163","article-title":"Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome","volume":"22","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key\n\t\t\t\t20171106135751_B35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"key\n\t\t\t\t20171106135751_B36","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.2013.51.0826","article-title":"Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"key\n\t\t\t\t20171106135751_B37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ejca.2015.05.005","article-title":"Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine\u2014results from the CONKO-001 trial","volume":"51","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B38","doi-asserted-by":"crossref","first-page":"e92320","DOI":"10.1371\/journal.pone.0092320","article-title":"Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression","volume":"9","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B39","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-015-2714-y","article-title":"Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer","volume":"75","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"key\n\t\t\t\t20171106135751_B40","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2012.46.9783","article-title":"Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine\/carboplatin in advanced non-small-cell lung cancer","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20171106135751_B41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.surg.2012.10.010","article-title":"Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection","volume":"153","year":"2013","journal-title":"Surgery"},{"issue":"7","key":"key\n\t\t\t\t20171106135751_B42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/bjc.2014.399","article-title":"Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy","volume":"111","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/his.12577","article-title":"Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies","volume":"66","year":"2015","journal-title":"Histopathology"},{"issue":"8","key":"key\n\t\t\t\t20171106135751_B44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17425255.2016.1192128","article-title":"Nucleoside analogs: ready to enter the era of precision medicine?","volume":"12","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"key\n\t\t\t\t20171106135751_B45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/0284186X.2015.1075663","article-title":"Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer","volume":"55","year":"2016","journal-title":"Acta Oncol"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/11\/4323\/21533646\/jc.2017-01624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T23:04:38Z","timestamp":1602975878000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jcem\/article\/102\/11\/4323\/4162024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,9,19]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01624","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,1]]},"published":{"date-parts":[[2017,9,19]]}}}